CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial

Access to chimeric antigen receptor (CAR) T cell therapy remains limited in many developing countries. We conducted a single-arm, open-label, phase 1 trial (NCT05333302) at two Belarusian centers, evaluating an in-house manufactured CD19 CAR T cell product (BY19) in pediatric and adult patients with...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mikalai Katsin, Dmitri Dormeshkin, Alexandr Migas, Olga Karas, Tatsiana Shman, Yuliya Serada, Yauheniya Khalankova, Hanna Klych, Dzmitry Lutskovich, Alena Lukoika, Alexander Meleshko
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-12-01
Col·lecció:	Molecular Therapy: Oncology
Matèries:	MT: Regular Issue CD19 CAR T cells decitabine B cell acute lymphoblastic leukemia B-ALL diffuse large B cell lymphoma
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S295032992500150X
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!